Related Experiment Video
Updated: May 6, 2026

Simple Continuous Glucose Monitoring in Freely Moving Mice
Published on: February 24, 2023
Unravelling dialysis-related dysglycaemia: Longitudinal insights from continuous glucose monitoring
Hellena Hailu Habte-Asres1,2, Ayodele Agbabiaka2, Roha Rehan2
1Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College London, London, UK.
Insights
Continuous glucose monitoring (CGM) in patients on maintenance hemodialysis showed initial improvements in time in range (TIR) that were not sustained. Hypoglycaemia burden increased over 12 months, highlighting the need for individualized diabetes management.
Area of Science:
- Endocrinology
- Nephrology
- Metabolic Diseases
Background:
- Diabetes management in patients undergoing maintenance hemodialysis is complex.
- Continuous glucose monitoring (CGM) offers detailed insights into glycemic control.
- Understanding glycemic trajectories and risks in this population is crucial.
Purpose of the Study:
- To characterize 12-month glycemic trajectories using CGM in maintenance hemodialysis patients.
- To assess changes in hypoglycemia burden and composite glycemic risk.
- To evaluate the utility of CGM for guiding individualized diabetes care.
Main Methods:
- Longitudinal observational study involving 125 maintenance hemodialysis patients.
- CGM data collected at baseline, 6, and 12 months.
- Analysis of time in range (TIR), time below range (TBR), time above range (TAR), glycemic variability (GV), hypoglycemia burden, and glycemic risk index (GRI).
Main Results:
- Time in range (TIR) improved at 6 months but declined by 12 months.
- Time below range (TBR) showed a small increase over time.
- Hypoglycemia burden increased significantly over the 12-month study period.
- Glycemic variability (GV) and glycemic risk index (GRI) remained largely unchanged.
- Moderate concordance observed between CGM and HbA1c.
Conclusions:
- CGM reveals dynamic glycemic patterns in hemodialysis patients.
- Initial glycemic improvements are not consistently maintained.
- Increased hypoglycemia burden necessitates careful monitoring and management.
- CGM data supports personalized diabetes management strategies focusing on safety and stability.
Aim:
To characterise CGM-derived glycaemic trajectories over 12months in people receiving maintenance haemodialysis, with a particular focus on hypoglycaemia burden and composite glycaemic risk.
Methods:
We conducted a longitudinal observational study. CGM data were collected at baseline, 6 and 12 months. Descriptive statistics summarised characteristics. Outcomes included time in range (TIR), time below range (TBR), time above range (TAR), glycaemic variability (GV), hypoglycaemia burden and glycaemic risk index (GRI). Metrics were summarised using means or medians, and changes between timepoints were assessed using paired t-tests or Wilcoxon signed-rank tests.
Results:
In 125 participants (mean age 63.7 years; 54.5% men), TIR increased from 51.6% at baseline to 56.6% at 6 months (mean difference 5.09%, 95% CI 1.06 to 9.12; p = 0.014) but was not sustained at 12 months (50.5%; p = 0.568), with a decline between 6 and 12 months (-6.11%, 95% CI -9.03 to -3.19; p < 0.001). TBR remained low, with a small increase between 6 and 12 months (1.61%, 95% CI 0.59-2.64; p = 0.002). TAR and GV were unchanged across timepoints. Hypoglycaemia burden increased over follow-up (p < 0.001), while GRI showed no change. HbA1c showed moderate concordance with CGM-derived glucose at baseline (ρ = 0.39; p = 0.0001) and 12 months (ρ = 0.59; p < 0.0001).
Conclusions:
CGM revealed evolving glycaemic patterns. Early improvements in TIR were not sustained, hypoglycaemia increased modestly and the overall GRI remained unchanged. These findings support CGM-informed, individualised diabetes management, prioritising safety and stability.
Related Concept Videos
Diabetic Nephropathy
Hyperglycemia
Type I Diabetes III: Clinical Manifestations
Complications of Diabetes Mellitus
Type I Diabetes II: Pathophysiology
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

